{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-117308","form_type":"8-K","ticker":"ELOX","cik":"0001035354","company_name":"Eloxx Pharmaceuticals, Inc.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.965110+00:00","generated_at":"2026-06-08T04:34:33.106558+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Eloxx reports Q3 net loss of $3.6M; positive Phase 2 data for ELX-02; Nasdaq delisting appeal pending","bullets":["Net loss of $3.6M ($1.31/share) vs. $7.5M loss a year ago; R&D expenses down to $1.3M from $4.9M.","Cash of $4.8M as of Sep 30; raised $3.8M in Q3; cash expected to fund operations only through end of Q4 2023.","Phase 2 open-label trial of ELX-02 in Alport Syndrome showed improved kidney morphology, collagen expression, and average 60% increase in filtration slit density.","Strategic partnership progress for ZKN-013; FDA clearance received for single ascending dose trial.","Common stock suspended on Nasdaq on Oct 16 and now trades on OTC Pink; appeal of delisting decision pending."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-117308","json":"https://secwatch.observer/filing/0001104659-23-117308.json","markdown":"https://secwatch.observer/filing/0001104659-23-117308.md","text":"https://secwatch.observer/filing/0001104659-23-117308.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1035354/000110465923117308/0001104659-23-117308-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1035354/000110465923117308/tm2330576d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T04:34:33.106558+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dca0447494622a41ff5f3d4a3eac96cd59459b26","claim":"Eloxx Pharmaceuticals, Inc. reported third fiscal quarter ended September 30, 2023 results: net income $3.6 million, EPS $1.31 per share.","evidence_excerpt":"For the three months ended September 30, 2023, we incurred a net loss of $3.6 million, or $1.31 per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465923117308/0001104659-23-117308-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third fiscal quarter ended September 30, 2023"},{"label":"Net income","value":"$3.6 million"},{"label":"EPS","value":"$1.31 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}